Medical

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |
[Total: 1    Average: 5/5]

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease has been awarded to MTPConnect, the growth centre for the medical technology, biotechnology, pharmaceutical and digital health sector.

“Diabetes and cardiovascular disease affects millions of Australians,” said the Minister for Health, the Hon Greg Hunt MP.

“Heart disease kills one Australian every 12 minutes, while diabetes causes more than one in ten deaths in our nation.”

Minister for Industry, Science and Technology Karen Andrews said the nature of the investment meant there was also great economic potential.

“You can’t put a price on health, but this investment will unlock collaboration that is going to save lives as well as commercialise ideas which can grow our economy and create Australian jobs. 

“A key focus of this accelerator will be on bringing new and innovative drugs and devices to market which can help Australians but also be sold to the world.

“The medtech sector is incredibly vibrant in Australia but the coronavirus pandemic has highlighted the opportunities for us to grow that even further.”

The MTPConnect Diabetes and Cardiovascular Accelerator (Accelerator) program will provide a new integrated research program to improve the management and treatment of diabetes and cardiovascular disease (D&CVD).

The Accelerator will:

  • Establish research centres for diabetes and cardiovascular disease
  • Establish a contestable funding program to support D&CVD research projects
  • Promote the clinical and commercial translation of novel therapeutics and devices for D&CVD

The Accelerator will be guided by an expert Board appointed by the Minister for Health and will work in partnership with leading D&CVD groups to improve the health and wellbeing of local, national and international communities through research, education and clinical practice.

The Accelerator will take a national and inclusive approach to working with clinicians, researchers, health administrators, Aboriginal and Torres Strait Islander health groups and consumers.

MTPConnect Managing Director & CEO, Dr Dan Grant, has welcomed the awarding of the program, through the Medical Research Future Fund (MRFF), which he says MTPConnect is uniquely placed to deliver.  

“At its core, the MTPConnect Accelerator will stimulate collaboration across relevant industry, research and clinical organisations and leverage strengths across the sector to ultimately produce novel preventative interventions, diagnostic and therapeutic approaches and products for D&CVD that reduce the burden on patients, families and communities,” he said.

“The TTRA program will drive a new focus on research efforts for the most pressing areas of unmet clinical and research needs in D&CVD, which are leading causes of death and disability in Australia,” Dr Grant said.

MTPConnect Chair Sue MacLeman says the MTPConnect Accelerator program will establish research centres for D&CVD, provide funding support and promote clinical and commercial translation.

“MTPConnect continues to make a valuable contribution to the growth of the MTP sector. Our Growth Centre work is now complemented by four Medical Research Future Fund programs worth nearly $147 million.Through our work fostering collaboration, addressing workforce challenges, opening-up international markets and optimising regulatory and policy frameworks we are playing a key role to drive Australia’s health and economic wellbeing,” Sue MacLeman said.

Details of partner organisations for the MTPConnect Accelerator will be announced soon.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - State first heart procedure with non-invasive technology most commonly used to combat cancer

State first heart procedure with non-invasive technology most commonly used to combat cancer

Health Industry Hub | August 4, 2020 |

MedTech News: A team of cardiologists and radiation oncologists from Fiona Stanley Hospital (FSH) and GenesisCare, have become the first […]

More


News & Trends - Pharmaceuticals

Pharma News - Medicines Australia calls for a focus in planning Australia's future in health

Medicines Australia calls for a focus in planning Australia’s future in health

Health Industry Hub | August 4, 2020 |

Pharma News: Medicines Australia Chief Executive Officer, Elizabeth de Somer has urged a focus on planning for the future – […]

More


News & Trends - Medical Technology

MedTech News - Australian-first procedure for chronic pain sufferers

Australian-first procedure for chronic pain sufferers

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Medical Technology’ sub-menu.

More


News & Trends - Pharmaceuticals

Pharma News - New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Pharmaceuticals’ sub-menu.

More